114 related articles for article (PubMed ID: 31222716)
1. Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
Djebbari F; Browning JA; Stanton L; Booth S; Hildyard C; Willan J; Bosworth J; Vora SM; Hatton CSR; Collins GP; Eyre TA
Br J Haematol; 2019 Sep; 186(6):e191-e195. PubMed ID: 31222716
[No Abstract] [Full Text] [Related]
2. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Fields PA; Townsend W; Webb A; Counsell N; Pocock C; Smith P; Jack A; El-Mehidi N; Johnson PW; Radford J; Linch DC; Cunnningham D
J Clin Oncol; 2014 Feb; 32(4):282-7. PubMed ID: 24220559
[TBL] [Abstract][Full Text] [Related]
3. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
Ji D; Li Q; Cao J; Guo Y; Lv F; Liu X; Wang B; Wang L; Luo Z; Chang J; Wu X; Hong X
Oncotarget; 2016 May; 7(22):33331-9. PubMed ID: 27129176
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma.
Gao Y; Xie Y; Liu L; Xue H; Hou M; Zhang M; Zhou Z; Guo P; Yao H; Shao Z; Xie X; Zhu J
Minerva Med; 2021 Apr; 112(2):310-312. PubMed ID: 31317691
[No Abstract] [Full Text] [Related]
6. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
8. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
9. Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma.
Nijland M; Bakker M; Meijer K; Plattel W
Ann Hematol; 2020 Dec; 99(12):2947-2948. PubMed ID: 32296911
[No Abstract] [Full Text] [Related]
10. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Davies A; Cummin TE; Barrans S; Maishman T; Mamot C; Novak U; Caddy J; Stanton L; Kazmi-Stokes S; McMillan A; Fields P; Pocock C; Collins GP; Stephens R; Cucco F; Clipson A; Sha C; Tooze R; Care MA; Griffiths G; Du MQ; Westhead DR; Burton C; Johnson PWM
Lancet Oncol; 2019 May; 20(5):649-662. PubMed ID: 30948276
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.
Cho KM; Keam B; Ha H; Kim M; Jung JW; Song WJ; Kim TM; Jeon YK; Kang HR; Kim DW; Kim CW; Heo DS
Korean J Intern Med; 2019 Jul; 34(4):885-893. PubMed ID: 29151283
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy.
Iioka F; Izumi K; Kamoda Y; Akasaka T; Ohno H
Int J Clin Oncol; 2016 Jun; 21(3):498-505. PubMed ID: 26463529
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP.
Kari E; Teppo HR; Haapasaari KM; Kuusisto MEL; Lemma A; Karihtala P; Pirinen R; Soini Y; Jantunen E; Turpeenniemi-Hujanen T; Kuittinen O
J Clin Pathol; 2019 Apr; 72(4):316-321. PubMed ID: 30755497
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma.
Ureshino H; Ando T; Kojima K; Itamura H; Jinnai S; Doi K; Ohshima K; Kurogi K; Miyahara M; Kimura S
Intern Med; 2015; 54(24):3205-8. PubMed ID: 26666614
[TBL] [Abstract][Full Text] [Related]
16. Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
Guidez S; Lacotte-Thierry L; Tomowiak C; Princet I; Dreyfus B; Olivier G; Fleck E; Corby A; Motard C; Barrier J; Machet A; Le Dû K; Debiais-Delpech C; Chabin M; Leleu X; Guilhot J; Delwail V
Br J Haematol; 2019 Sep; 186(6):e175-e178. PubMed ID: 31309541
[No Abstract] [Full Text] [Related]
17. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
18. Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma.
Eyre TA; Salisbury R; Eyre DW; Watson C; Collins GP; Hatton CS
Br J Haematol; 2016 May; 173(3):487-91. PubMed ID: 26223361
[No Abstract] [Full Text] [Related]
19. Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
Campiotti L; Suter MB; De Palma D; Proserpio I; Uccella S; Squizzato A
Hematol Oncol; 2019 Aug; 37(3):308-309. PubMed ID: 30933368
[No Abstract] [Full Text] [Related]
20. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Zhang WH; Li GY; Ma YJ; Li ZC; Zhu Y; Chang J; Hao SG; Tao R
Ann Hematol; 2018 Oct; 97(10):1809-1816. PubMed ID: 29754271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
